Lv1
60 积分 2024-09-24 加入
Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives
2个月前
已完结
Mechanistic insights into Wnt–β-catenin pathway activation and signal transduction
2个月前
已完结
Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation
2个月前
已完结
Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer
3个月前
已完结
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation
3个月前
已完结
Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors
3个月前
已完结
Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches
3个月前
已完结
Opportunities and challenges of targeting cGAS–STING in cancer
3个月前
已完结
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
3个月前
已完结
Aptamers Targeting the PD-1/PD-L1 Axis: A Perspective
3个月前
已完结
皖公网安备34019202002308
